News

The collaboration and license agreement will see both companies evaluate novel bispecific immuno-oncology agents that combine Pieris’ anticalin technology with select Seattle Genetics cancer-targeted antibodies. The companies will

Ozempic is a new once-weekly analogue of human glucagon-like peptide-1 (GLP-1) indicated as monotherapy when metformin is considered inappropriate due to intolerance or is contraindicated, and as an

The placebo-controlled trial was held in over 1,200 men with nonmetastatic, castration-resistant prostate cancer, who were at high risk for the development of metastasis in spite of being

Under the terms of the agreement, Haichang will develop a nano-liposomal formulation of RX-0201 using its proprietary QTsome™ technology and conduct certain pre-clinical and clinical activities through completion

The updated label includes Cosentyx data in moderate-to-severe scalp psoriasis – one of the difficult-to-treat forms of the disease, which affects approximately half of all psoriasis patients. The

Bictegravir is one of the three drugs used in Biktarvy, which secured approval from the US Food and Drug Administration (FDA) for the treatment of human immunodeficiency virus type

Bexsero is the first vaccine in the world to receive the Breakthrough Therapy Designation (BTD) twice. In 2014, Bexsero received BTD for development in the prevention of IMD

The companies have signed a global co-development and commercialization agreement that could generate up to $1bn for Theravance. Theravance's TD-1473 is an internally-discovered Janus kinase (JAK) inhibitor that has demonstrated

AstraZeneca announced results from a new sub-analysis of the Phase III PEGASUS-TIMI 54 trial, demonstrating a risk reduction of 19% in MACE (the composite of CV death, myocardial infarction,